Analysts Ratings on: Momenta Pharmaceuticals Inc. (MNTA)

1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data. Earlier, Momenta suffered a blow when the FDA approved Mylan's generic version of Copaxone 40 mg. The company's past year sales total was 34200.

MNTA has been the topic of a number of analyst reports. Maxim Group set a $6.00 price objective on shares of Momenta Pharmaceuticals and gave the stock a "sell" rating in a research report on Tuesday, November 29th. They issued a "neutral" rating and a $18.00 price target on the stock. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a "hold" rating to a "buy" rating and set a $20.00 target price on the stock in a research note on Wednesday, October 4th. Cowen set a $15.00 price target on shares of Momenta Pharmaceuticals and gave the company a "hold" rating in a research report on Wednesday, November 1st. BidaskClub cut Momenta Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, December 7th. Stifel Nicolaus reiterated a "hold" rating and issued a $15.00 target price (down from $22.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $14.44.

John Malkovich joins Zac Efron in tale of serial killer Ted Bundy
The Con Air actor is set to play Judge Edward Cowert, who presided over Bundy's trial in 1979 and sentenced him to death. Shortly before his execution, he confessed to 30 homicides committed in seven states between 1974 and 1978.

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) traded up $0.40 on Monday, hitting $14.30. The stock had a trading volume of 987,700 shares, compared to its average volume of 1,157,357. The company has a market cap of $1,100.00, a P/E ratio of -17.31 and a beta of 1.66. Momenta Pharmaceuticals has a 12 month low of $11.85 and a 12 month high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Wednesday, November 1st. BlackRock Fund Advisors now owns 5,258,020 shares of the biotechnology company's stock valued at $61,466,000 after buying an additional 335,064 shares in the last quarter. The business had revenue of $24.09 million for the quarter, compared to analysts' expectations of $29.58 million. Return on Equity (ROE) stands at -16.2% and Return on Investment (ROI) of -20.1 percent. The firm's quarterly revenue was down 17.3% compared to the same quarter last year. analysts expect that Momenta Pharmaceuticals will post -1.16 EPS for the current fiscal year. Momenta Pharmaceuticals earned a news sentiment score of 0.13 on Accern's scale. The shares were sold at an average price of $13.10, for a total value of $72,050.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Bristol-Myers Squibb Co (BMY) Shares Sold by OLD Republic International Corp
Whereas the traders who further want to see about this, may be interested to see Price to next year's EPS that would be 5.43%. The stock of Bristol-Myers Squibb Company (NYSE: BMY ) has "Sell" rating given on Monday, June 5 by BMO Capital Markets.

In other Momenta Pharmaceuticals news, CEO Craig A. Wheeler sold 35,666 shares of the company's stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.11, for a total transaction of $503,247.26. The disclosure for this sale can be found here. In the last three months, insiders sold 49,505 shares of company stock worth $685,923. Corporate insiders own 6.10% of the company's stock. FMR LLC increased its position in Momenta Pharmaceuticals by 2.6% in the second quarter. Following the sale, the director now directly owns 13,240 shares in the company, valued at $173,444. Can lifted its position in shares of Momenta Pharmaceuticals by 8.4% during the 2nd quarter. Principal Financial Group Inc. now owns 606,700 shares of the biotechnology company's stock valued at $11,224,000 after buying an additional 65,014 shares in the last quarter. Vanguard Group Inc. increased its position in Momenta Pharmaceuticals by 4.9% during the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company's stock worth $109,000 after buying an additional 834 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Momenta Pharmaceuticals by 8.6% during the 2nd quarter. Profund Advisors LLC increased its stake in Momenta Pharmaceuticals by 13.1% during the 2nd quarter. Palo Alto Investors LLC now owns 1,787,576 shares of the biotechnology company's stock valued at $30,210,000 after acquiring an additional 28,200 shares during the last quarter. However, the institutional investors are observed to own N/A of the total shares.

ILLEGAL ACTIVITY WARNING: "Momenta Pharmaceuticals (NASDAQ:MNTA) Stock Rating Upgraded by Zacks Investment Research" was first posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another website, it was illegally stolen and republished in violation of USA & global copyright laws.

Bumrah: India confidence not dented
In comparison to the pensive Indian camp, South Africa seemed at ease as they went about practicing for the second Test. That's one reason why we have won many games in the past is because we have applied ourselves really well.

Many analysts have provided their estimated foresights on Momenta Pharmaceuticals Inc. The companyÂ's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Últimas notícias